Formycon AG (LON:0W4N)
19.82
-1.13 (-5.39%)
At close: Nov 5, 2025
Formycon AG Revenue
Formycon AG had revenue of 9.00M EUR in the half year ending June 30, 2025, a decrease of -79.45%. This brings the company's revenue in the last twelve months to 51.78M, down -14.84% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
51.78M EUR
Revenue Growth
-14.84%
P/S Ratio
7.01
Revenue / Employee
207.11K EUR
Employees
250
Market Cap
310.97M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Formycon AG News
- 16 days ago - Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe - Nasdaq
- 5 weeks ago - Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes - Nasdaq
- 7 weeks ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista